Research Article

Transgenic Rat Model of Huntington’s Disease: A Histopathological Study and Correlations with Neurodegenerative Process in the Brain of HD Patients

Yvona Mazurová,1 Miroslava Anderová,2 Ivana Němečková,3 and Aleš Bezrouk4

1 Department of Histology and Embryology, Faculty of Medicine in Hradec Králové, Charles University in Prague, Šimkova 870, P.O. Box 38, 500 38 Hradec Králové, Czech Republic
2 Department of Cellular Neurophysiology, Institute of Experimental Medicine, The Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
3 Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
4 Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University in Prague, Šimkova 870, P.O. Box 38, 500 38 Hradec Králové, Czech Republic

Correspondence should be addressed to Yvona Mazurová; mazurova@lfhk.cuni.cz

Received 9 May 2014; Revised 26 June 2014; Accepted 26 June 2014; Published 3 August 2014

Academic Editor: Mahendra P. Singh

Copyright © 2014 Yvona Mazurová et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rats transgenic for Huntington’s disease (tgHD51 CAG rats), surviving up to two years, represent an animal model of HD similar to the late-onset form of human disease. This enables us to follow histopathological changes in course of neurodegenerative process (NDP) within the striatum and compare them with postmortem samples of human HD brains. A basic difference between HD pathology in human and tgHD51 rats is in the rate of NDP progression that originates primarily from slow neuronal degeneration consequently resulting in lesser extent of concomitant reactive gliosis in the brain of tgHD51 rats. Although larger amount of striatal neurons displays only gradual decrease in their size, their number is significantly reduced in the oldest tgHD51 rats. Our quantitative analysis proved that the end of the first year represents the turn in the development of morphological changes related to the progression of NDP in tgHD51 rats. Our data also support the view that all types of CNS glial cells play an important, irreplaceable role in NDP. To the best of our knowledge, our findings are the first to document that tgHD51 CAG rats can be used as a valid animal model for detailed histopathological studies related to HD in human.

1. Introduction

Huntington’s disease (HD) is an autosomal dominant inherited disorder belonging to the group of systemic brain atrophies. General clinical symptoms are defined by early changes in personality and cognitive functions, followed by typical involuntary choreatic movements; advanced stages of the disease include bradykinesia, rigidity, and dementia. The first symptoms appear frequently between 35 and 50 years of age. The disease is always fatal with an average survival of 10–15 years after the onset of the first symptoms. The disease may develop at any time, even during childhood and adolescence. Of note, juvenile form of HD represents 6% of HD patients [1].

Histopathologically, HD is characterised by premature death particularly of medium-sized (mainly GABA-ergic) striatal neurons but large interneurons are mostly spared (e.g., [2]). Regardless of the development of reactive gliosis within the striatum, loss of the grey matter is extensive and results in the compensatory enlargement of lateral brain ventricles. Due to the general atrophy, the brain weight can decrease by 40% (e.g., [3]).
Severity of the degeneration is evaluated using grading system proposed by Vonsattel and coauthors [2], which classifies HD into five grades (0–4). In grade 0, patients have already clinical symptoms; however, neuronal loss in the head of the caudate nucleus (CN) can be detected only on microscopic level. In grade 1, neuronal loss is accompanied by reactive gliosis, which is evident primarily in the head and tail, less in the body of CN. Grade 2 is characterised by mild to moderated striatal atrophy. In grade 3, due to the progression of atrophy, the medial outline of the CN becomes straight. In grade 4, neuronal loss is a keystone (reaches 95%) and therefore the medial part of the CN is concave. Moreover, brains from patients with late onset of clinical symptoms might show changes occurring in usual aging in addition to those observed in HD (e.g., [2]).

Genetic mutation on short arm of chromosome 4, which causes HD, was discovered in 1983 [4]. Lately, in 1993, gene IT15 (interesting transcript 15), which codes unstable protein huntingtin (htt) comprising variable number of CAG repeats, was identified [5]. Such molecular defect is based on the expansion of this triplet that codes amino acid glutamine. Therefore, HD can be included into the group of polyglutaminopathies.

Mutant form of huntingtin (mhtt) comprises up to 40 repeats and individuals with 36–39 CAG repeats are in risk of developing adult (late-onset) form of HD. Juvenile form of HD develops in patients with 55 and more repeats (e.g., [6]). Although wild-type huntingtin is expressed in all cell types, with the highest concentration in the brain [7], its functions are not yet fully understood [8]. Expanded polyglutamine forms intracellular deposits, particularly in a form of intranuclear and neuropil aggregates (e.g., [8, 9]). It is evident that mhtt displays specific toxicity to striatal (mainly GABA-ergic), less cortical neurons. However, the role of mhtt in the pathogenesis of HD appears highly controversial, ranging from being essential in pathogenesis of the disease (e.g., [6, 8]) to being neuroprotective [10, 11]. Moreover, mhtt also accumulates in nuclei of astrocytes causing their dysfunction, particularly in relation to glutamate uptake. This may further promote vulnerability, especially of striatal medium-sized spiny neurons, to the excitotoxic damage [12]. Therefore, turning our attention to glutamate uptake in astrocytes might be of particular importance for preventing glutamate excitotoxicity in HD [12, 13]. Nevertheless, the presence of mhtt in neural cells is not the only mechanism, which is involved in HD pathogenesis. Metabolic and mitochondrial dysfunctions, oxidative and nitrosative stress, and also apoptosis play an important role as well (e.g., [14]).

Generation of transgenic mice as well as transgenic rats advanced significantly the understanding of HD pathology. Indeed, over 20 different rodent models of this disease have been generated to date (for the review see [15]). The firstly introduced transgenic model of HD termed R6 [16] and other generated lines, such as R6/1 and R6/2 (with 115 and 145 CAG repeats, resp.), belong to the most frequently used models of HD (e.g., [17, 18]). These models of HD are characterized by early onset and fast progression of behavioural deficits (later also by motor dysfunction) and presence of intranuclear polyglutamine (polyQ) inclusions (4 weeks postnatally), but without the evident reduction of neurons even in aged mice [16, 19]. Therefore, they simulate rather juvenile than adult form of HD.

In 2003, von Hörsten and coworkers generated the first transgenic rat model of HD (tgHD51 rats; Sprague-Dawley background), which carries a truncated htt cDNA fragment with 51 CAG repeats under the control of the native rat htt promoter [20]. Due to relatively smaller number of CAG repeats, this model exhibits a high degree of similarity to the late-onset form of HD. These rats survived up to 24 months and exhibited slow cognitive decline and not as much of motor deficit (e.g., [9, 20–24]). Neuropil aggregates of polyglutamine and typical intranuclear inclusions in neurons appeared in the brain approximately at 6–9 months of age [9]. Despite the fact that tgHD51 rats displayed enlarged lateral brain ventricles, stereological analysis revealed only a subtle decrease in the number of neurons in the striatum, while no changes were observed in number of neurons in the frontal cortical layer V of 12-month-old tgHD51 rats when compared with age-matched wild-type controls [24].

Astrocytes are the most numerous type of glial cells in mammalian CNS. Currently, they are considered as highly active cellular component of the CNS parenchyma with functional pleiotropy essential for neuronal survival and function (e.g., [25–27]). Besides others, they are closely associated with neuronal synapses (“tripartite synapse”—[28]), secrete and degrade proteins of extracellular matrix, and are responsible for uptake and release of different neurotransmitters, primarily of the glutamate. It has been suggested that enhanced release of glutamate and other substances may represent an early event in a number of, if not all, neurodegenerative diseases (e.g., [29]).

The communication between neurons and local blood flow mediated by astrocytes is elementary for the maintenance of functional microenvironment in the grey matter of the entire CNS parenchyma; therefore the term neuronal-glial-vascular unit is used [30]. On the other hand, under pathological conditions, the perivascular end-feet can restrict transport or diffusion across the blood-brain interface [31].

Glial fibrillary acidic protein (GFAP [32]) is essential for immunohistochemical identification of astrocytes. However, GFAP is densely expressed only within the cell body and larger processes of astrocytes, unlike the numerous fine processes representing the majority of the total volume of the astrocytes, which are GFAP-negative [30]. Any type of the CNS injury (primarily the acute damage) initiates morphological changes of some astrocytes, which become reactive (e.g., [33]). They are hypertrophic with longer and thicker main processes and increased expression of GFAP due to the formation of bundles of gliofilaments (e.g., [34]). In the acute phase of reaction, astrocytes also reexpress intermediate filaments significant for glial precursors—nestin and vimentin (e.g., [35, 36]).

Beta-subunit of Ca$^{2+}$ binding protein (SI00β) is another putative astrocytic marker (e.g., [37]). SI00β is produced, stored, and released primarily by astrocytes; however, it is also expressed by many other cells in the CNS and other body regions. SI00β is localized in the cytoplasm and nucleus and
involved in the regulation of a number of cellular processes (e.g., [38, 39]). Regardless of large body of studies, only few of them are dealing with morphology of S100β cells (e.g., [39, 40]). Most of experimental or clinical studies are related to detection of concentrations of S100β within the tissue, or its plasma (or CSF) levels, whose changes are significant for various diseases, probably due to release of S100β from damaged astrocytes (e.g., [38]).

NG2 glia (polydendrocytes or synantocytes) represent a fourth type of glia in the CNS (e.g., [41]). They exist abundantly in both grey and white matter of the mature CNS in rodents as well as human. They constitute the major group of cells undergoing mitosis in the adult rodent brain and are almost as numerous as astrocytes [42]. NG2 cells are primarily described as the precursors of myelinating oligodendrocytes (OLPs). However, many of the NG2 cells remain in the NG2-positive state for a significant time and have a unique capacity to communicate with nearby cells, forming multiple contacts with astrocytes, microglia, oligodendrocytes, and even neurons [43]. In human brain, significant morphological changes related to the progression of pathology were studied particularly in multiple sclerosis and gliomas [44].

Microglia, the immunocompetent highly motile cells of the CNS, are extremely plastic and undergo a variety of structural changes based on their location and current role [45]. In the grey matter, the most frequent is ramified form, which express protein Iba1 (ionized calcium-binding adapter molecule 1) also known as AIF-1 (allo graft inflammatory factor 1). The density of this marker significantly increases with activation of cells. It is obvious that the activation of microglia is a basic mechanism in the defence of the CNS, also in relation to neurodegenerative processes (e.g., [45, 46]). Although the role of microglia in neurodegeneration is still controversial, it is evident that in human brain they are activated in early stages of NDP of different phenotype, primarily in HD (e.g., [46, 47]), Parkinson’s disease (e.g., [48]), and Alzheimer’s disease (e.g., [49, 50]). It is possible that microglia transform to phagocytes and target neurons as the disease progresses but appear to be dysfunctional with increasing amounts of ingested debris [48].

It is commonly known that the neurodegenerative process of HD phenotype is a chronic process, morphologically characterized by the progressive degeneration of neurons, principally in the striatum, but gradually affecting almost all parts of the brain. This results in a reduction of grey matter and brain atrophy with compensatory enlargement of the lateral brain ventricles. Nevertheless, also as the second component of the brain parenchyma, the glial cells play an irreplaceable role in this process. The reaction of astrocytes to any damage of the CNS parenchyma in a sense of their conversion into the reactive intensely GFAP-positive subset is well known already for long time. Although the participation of other types of glial cells, particularly of microglia and NG2 glia, in neurodegenerative process has been studied in last two decades, the histopathological interrelations among all above-mentioned cell types have not been well described yet. Moreover, the validation of existing transgenic rat model of HD51 from this point of view is still lacking.

2. Materials and Methods

All animal procedures were performed in accordance with the directive of the EEC (86/609/EEC) and the use of animals in our experiments was reviewed and approved by the Animal Ethical Committee of Charles University in Prague, Faculty of Medicine in Hradec Králové.

2.1. Animals. Male homozygous tgHD51 CAG rats (+/+; n = 18) and their wild-type (wt) littermates (−/−; n = 18) were obtained from H. P. Nguyen and O. Riess, the Department of Medical Genetics, University of Tübingen, Germany. Rats were sacrificed at the age of 2 or 3 months (tgHD n = 3; wt n = 2), 6 months (tgHD n = 2; wt n = 3), 12 months (tgHD n = 4; wt n = 5), 18 months (tgHD n = 5; wt n = 4), and 22–24 months (tgHD n = 4; wt n = 4).

2.2. Postmortem Specimens. The brains of three patients with approximately 2-, 8-, and 20-year clinical manifestations of HD (sex/age: 8/52, 82/38, and 8/52) were studied. Three control brains of patients (sex/age/weight: 6/33/1440 g, 6/43/1510 g, and 6/56/1400 g) with no history of neurologic disorder or brain lesion were also taken for the study. The clinical features of HD (described in autopsy records) were characteristic for the given stages in all three patients. However, detailed neurological records or results of genetic testing were not available because old archival material was used. Surprisingly, the total brain weight was markedly reduced in all HD cases independent of the sex and duration of the illness (duration/sex/weight: 2 y/♂/2160 g, 8 y/♀/1150 g, and 20 y/♀/1120 g) in comparison with control human brains. The severity of striatal histopathological changes was graded (grades 0–4) according to Vonsattel and coauthors [2].

Paraffin blocks of brain tissue from autopsies were taken from the neostriatum (the caudate nucleus and putamen) at the level of the globus pallidus and at the level of the nucleus accumbens. The blocks were donated by Fingerland’s Department of Pathology, Faculty Hospital in Hradec Králové.

2.3. Histology and Immunohistochemistry. Animal brains were processed either with formalin fixation (4% neutral formaldehyde) and embedded in paraffin or with 4% paraformaldehyde (in 0.1 M phosphate buffer) fixation and frozen sections preparation. The transcardial perfusion with fixative solution under deep anaesthesia followed by postfixation (for 3 days or 2 hours, resp.) was made in all animals. Brains were transversely cut using the Brain Blocker (Better Hospital Equipment Corp., USA) to obtain the identical blocks of brain tissue. After postfixation, the brain hemispheres were separated and processed separately.

2.3.1. Paraffin Sections. Histological processing was the same for both the experimental material and autopsies. Serial coronal sections (7 μm thick; 120 sections per each rat brain hemisphere), prepared by conventional histological processing, allowed us to study the same region with different antibodies. Findings obtained by immunofluorescent detections (double-labelling) were mostly confirmed by a single
Table 1: Antibodies used.

| Antibody             | Host          | Dilution | Source     | Report                      |
|----------------------|---------------|----------|------------|-----------------------------|
| Nestin               | Rat monoclonal anti-mouse | 1:4      | DSHB       | Progenitor cells marker     |
| Nestin               | Mouse monoclonal anti-human | 1:200    | Millipore  | Progenitor cells marker     |
| β-III tubulin        | Mouse monoclonal | 1:20     | Exbio      | Neuronal marker             |
| MAP2                 | Mouse monoclonal | 1:500    | Sigma-Aldrich | Neuronal marker            |
| MAP2                 | Rabbit polyclonal | 1:700    | Millipore  | Neuronal marker             |
| NeuN                 | Mouse monoclonal | 1:100    | Millipore  | Marker of mature neurons    |
| Synaptophysin        | Mouse monoclonal | 1:20     | Dako       | Marker of neuronal synapses  |
| Vimentin (Cy3 conjugated) | Mouse monoclonal | 1:100    | Sigma-Aldrich | Astrocyte and radial glia marker |
| NG2                  | Rabbit polyclonal | 1:400    | Millipore  | Oligodendrocyte precursor and pericyte marker |
| APC                  | Mouse monoclonal | 1:200    | Calbiochem | Oligodendrocyte and astrocyte marker |
| GFAP                 | Mouse monoclonal | 1:400    | Sigma-Aldrich | Astrocyte marker            |
| S100β                                                                 |
| S100β                                                                 |
| Iba1                 | Mouse monoclonal | 1:300    | Millipore  | Microglia and macrophage marker |
| PolyQ-huntingtin     | Mouse monoclonal | 1:20000  | Millipore  | Polyglutamine inclusions marker |

antibody detection using peroxidase-antiperoxidase (PAP) immunohistochemistry on parallel paraffin sections.

2.3.2. PAP Immunohistochemical Detection. For immunohistochemical detection, deparaffinized and rehydrated sections were used. Pretreatment in microwave 3 × 5 min at 800 W in the sodium citrate buffer (pH 6.0) and washing in 0.01 M PBS was mostly performed. For detection of polyglutamine deposits the pretreatment with 98% formic acid (5 min at room temperature) was required. Incubation in blocking solution (water solution of H₂O₂) for 20 min was followed by incubation with primary antibodies (Table 1) performed overnight at 4°C. Sections were then washed and incubated with the appropriate biotinylated secondary antibody (Jackson ImmunoResearch Lab., USA, 1:500) for 45 min at room temperature and subsequently with a streptavidin conjugate of peroxidase (Dako, CR) also for 45 min. Visualization of bound antibody was performed using DAB (Sigma-Aldrich, CR) and H₂O₂.

2.3.3. Cryostat Sections. Postfixed blocks of rat brains were placed stepwise in solutions with gradually increasing sucrose concentrations (10%, 20%, and 30%) for cryoprotection at 4°C. Serial coronal cryostat free-floating sections (30 μm thick) were cut. The slices were incubated with 5% Chemiblocker (Millipore, MA, USA) and 0.2% Triton in PBS at 4°C.

2.3.4. Immunofluorescent Double-Labelling Technique. The sequential technique for immunofluorescent double-labeling of antibodies (Ab) was same for both types of sections. Avidin or appropriate secondary Ab was labelled with Cy-3 or Alexa Fluor 660 (red) and with Alexa Fluor 488 or 594 (green) and nuclei were counterstained with DAPI (blue). The negative control, omitting the primary antibody, was made in each labelling.

Photomicrographs were made with Lucia G/F software version 4.82 (Laboratory Imaging, Prague, Czech Republic) or Quick Photo Camera 2.3 software (Promicra, Prague, Czech Republic).

2.4. Quantitative Analysis. In order to characterize the progression of NDP in the striatum of tgHD51 rats, we used the quantitative analysis of the median diameter of neuronal nuclei as a marker of proposed significant process in a course of neurodegeneration in tgHD rats; it means the shrinkage of striatal neurons. We would like also to determine the onset of significant neuronal degeneration in the striatum of tgHD51 rats and the possible participation of age-related changes.

The region of rat brain, used for analysis, was determined according to the brain atlas [51] from the level 14 (+0.95 from bregma) dorsally in a sequence of 3 slices, each 7 μm thick, in the distance of 15 sections (i.e., approximately 105 μm); it means that analysed part of rat brain was of about 220 μm.
thick. Selected sections were labelled with NeuN antibody, which marks selectively the nuclei of mature neurons, using the PAP immunohistochemical detection.

The groups of tgHD and wt rats were divided into two basic subgroups of “young” 3- and 6-month-old (0–6 months) and “old” 12-, 18-, and 24-month-old (>6 months) rats. The number of analysed sections was the following: 6 sections in the “young_wt” group, 6 sections in the “young_tgHD” group, 18 sections in the “old_wt” group, and 24 sections in the “old_tgHD” group. Neuronal nucleus median diameter was obtained from 50 independent measurements in the central area of the striatum on each analysed section. Due to possible distortions of the shape of neuronal nucleus in the section, the largest size of the nucleus was considered the nucleus diameter. Each group of rats of the same age was represented by the set of all medians in given group.

2.5. Statistical Analysis. Statistical analyses of the differences between groups were performed using MS Excel 2007 (Microsoft Corp., Redmond, WA, USA) and NCSS 2007 (NCSS LLC, Kaysville, Utah, USA). The median diameters were compared using Kruskal-Wallis Multiple-Comparison Z-Value Test (Dunn’s Test). The test with Bonferroni correction was used to adjust multiple comparisons with the family-wise α at 0.05.

3. Results

In tgHD31 rats, the NDP in the striatum starts to develop only after 6 months of age. Surprisingly, the most distinct changes in striatal grey matter develop by the end of the first year of age (probably between 9 and 12 months). The end of the first year represents the turn in the development of morphological changes related to the progression of NDP within the striatum of tgHD31 rats. These findings correspond to the course of HD in human brain, where the motor and behavioural changes precede the loss of striatal neurons [20]. We demonstrate possible parallels between the HD progression in humans and the above-described transgenic rat model and prove the validity of our findings for human HD pathology. The cases demonstrated here represent the sequence of 3 stages (grades 1-2, grade 3, and grade 4) of the progression of HD in human brain.

It is almost impossible to dissociate the alterations referring to neurons and glia in a course of NDP because of very close relationship and mutual influence of both main components of striatal parenchyma. However, we would like to stress some features specific for each of them in a course of the development of NDP within the striatum of both rat and human brains. For that reason, we described their involvement in progression of NDP separately.

3.1. Neuronal Degeneration during the Progression of HD. When we compare the brains of 2- and 3-month-old, (young adult) wild-type and tgHD rats, there is no difference in morphology of the striatum. Also lateral brain ventricles are narrow, of the same shape in both mentioned groups (Figure 1(a)). Only in 12-month-old tgHD31 rats appears the identifiable enlargement of lateral ventricles, which documents developing striatal atrophy. The process gradually progresses resulting in prominent widening of lateral ventricles (Figure 1(b)), with concave medial outline of the striatum in the oldest (22–24-month-old) tgHD rats, which is fully comparable with the progression of HD in human brain.

3.1.1. Degeneration of Striatal Neurons. Striatal neurons (β-III-tubulin+/MAP2+) or their nuclei (NeuN+ or DAPI+) form typical clusters in all tested groups of wt (e.g., Figures 2(a), 2(b), and 3(a)) and tgHD rats (e.g., Figures 2(c)–2(f) and 3(b)) and in human postmortem samples of intact striatum (Figure 4(a)). However, with the progression of HD in humans, gradual decrease in number of neurons is significant, particularly in advanced stages of HD (grade 3—Figure 4(b) and grade 4—Figure 4(c)).

Nuclei of striatal neurons are very characteristic, especially due to their large size and fine loosely arranged chromatin in comparison with significantly smaller nuclei with more densely arranged chromatin of glial cell. Despite the fact that striatal neurons become gradually smaller in course of HD progression (compare Figures 3(a) and 3(b)), such specific features of neuronal and glia nuclei always enable their distinguishing. Our immunohistochemical analysis of neuronal nuclei by NeuN shows slow but already significant progression of neuronal degeneration in the striatum from 12 to 24 months of age of tgHD rats (Figure 3(b)) when compared with age-matched controls (Figure 3(a)) and younger tgHD rats. The most typical for NDP in tgHD31 rats is a gradual decrease in size of neuronal bodies and nuclei (with maintenance of nucleo-cytoplasmic rate), which results in the disintegration and disappearance of affected neurons (Figures 2(d)–2(f)), ultimately scavenged by microglia (Figures 12(b) and 12(c)).

In the human HD brain, grades 1-2 (with approximately 2-year clinical manifestation), the degeneration and loss of neurons were only random; therefore, the loosening of the neuropil has not been apparent yet. On the other hand, in grade 3 (approximately 8-year clinical history), neuronal degeneration was already obvious (Figure 4(b)). Depletion of neurons (particularly in the CN and putamen (Pu)) accompanied with rarefaction of the neuropil resulted in a reduction of striatal volume and noticeable enlargement of the lateral ventricles. In grade 4 (with approximately 20-year clinical diagnosis) the entire corpus striatum (CN, Pu, and globus pallidus) was affected by degeneration of neurons and neuropil (resulting in severe striatal atrophy) and therefore the concomitant astrogliosis here prevailed (Figures 4(c), 10(b), and 10(c)). The remaining striatal neurons (marked by their prominent nuclei) gradually became smaller with the progression of NDP, like in the brain of tgHD rats.

Additionally, we confirmed that, alike in human HD brain, neuronal degeneration is selective, that is, affecting primarily certain groups of neurons in the striatum of investigated senescent tgHD rats and moreover that age-related changes contribute to final extent of NDP.
3.1.2. Quantitative Analysis of Neuronal Degeneration in the Striatum of tgHD Rats. We supposed that neuronal degeneration in the striatum of tgHD rats manifests primarily by the decrease in a volume/size of neuronal bodies including their nuclei. In order to precisely characterize the progression of NDP within the striatum of tgHD51 rats, our morphological findings were supplemented by quantitative analysis of the diameter of neuronal nuclei labelled with NeuN. Also the proportion of age-related changes in this process was assessed.

The progression in decrease of the median diameter of neuronal nuclei with age of rats in both wt and tgHD groups of rats is documented by Progress Chart (Figure 5(a)).
In the first two groups of rats, that is, 2-3-, and 6-month survivors, no differences in the median diameter of NeuN-positive nuclei were detected when compared within the individual group or among the groups. Striking decrease in the median diameter of neuronal nuclei by 26% was detected in 12-month-old tgHD rats unlike the parallel wt group, in which the decrease was only 7.6%, when compared with the youngest animals in both mentioned groups. Surprisingly, further progression in decrease of the median diameter of neuronal nuclei was not so rapid; however, finally the reduction reached 28.7% in 24-month-old tgHD rats, when compared with age-related degeneration in 24-month-old wt rats (only 8.3%).

Statistical characteristic of the groups of rats using Box Plot (Figure 5(b)) enables the multiple comparison of the median diameter of neuronal nuclei of the following groups of rats: “young wt” and “young_tgHD” are groups of rats 3 and 6 months (0–6 months) old; “old_wt” and “old_tgHD” are groups of rats 12, 18, and 24 months old (>6 months). Results of Kruskal-Wallis Multiple-Comparison Z-Value Test (Dunn’s Test) of the mentioned groups of rats (Table 2) indicate significantly different pairs of groups (Bonferroni test: medians are significantly different if Z-value is > 2.6383). Statistically significant is a difference in the median diameter of neuronal nuclei in “old_tgHD” group in comparison with all other evaluated groups.

| Group       | young_tgHD | young_wt | old_tgHD | old_wt |
|-------------|------------|----------|----------|-------|
| young_tgHD  | 0.2844     | 4.9557*  | 1.813    | 4.5135* |
| young_wt    | 4.9557*    | 4.5959*  | 1.4646   | 4.5135* |
| old_tgHD    | 1.813      | 1.4646   | 4.5135*  |       |
| old_wt      | 4.5135*    | 4.5135*  | 4.5135*  |       |

It is evident that the median diameter of neuronal nuclei in “old_tgHD” group is significantly statistically different from all other evaluated groups. Differences among three remaining groups are statistically insignificant.
We can conclude that the rate of neuronal degeneration reaches maximum at the end of the first year of animal’s age and then, in the following 12 months, it proceeds rather slowly. Moreover, it is potentiated with age-related changes particularly in the oldest animals. Unexpectedly, the transitional amelioration of the process up to slight improvement appeared in both groups (wt and tgHD) of 18-month survivors. Neuronal degeneration in wt rats can be attributed only to the debit of the aging process; the decrease in size of nuclei was slow and the difference between 2-3-month-old rats and 24-month-old ones was only 8.3% (Figure 5(a)).

3.1.3. Rarefaction of Neuropil and Alterations in Morphology of Synapses. Striatal atrophy, in the case of HD, is primarily caused by the degeneration of striatal neurons. Of course, the most prominent feature, seen on histological preparations, is a gradual reduction of neuronal bodies marked by the nuclei. Indeed, the reduction in a volume of neuropil is at least of the same importance. Large amounts of dendrites (with dendritic spines) extending from neuronal bodies (labelled with anti-MAP2—Figure 12, less with anti-β-III-tubulin—Figure 2) with myriads of synapses represent the essential component of the neuropil. Although the rarefaction of neuropil is not based only on the degeneration of this network of neuronal processes and synapses, it demonstrates the progression of such process in both human and rat brains (Figures 8(a)–8(d)). In addition, we also proved the alterations in a character of synapses. In control brains of both rats and humans, synaptophysin-positive synapses are very fine, of uniform size and shape, and plentiful (Figures 6(a) and 7(a)). With the progression of NDP, most of synapses become coarser, more prominent, but of variable size, and some of them are intensely labelled for synaptophysin; consequently, their number gradually decreases (Figures 6(b) and 7(b)).

3.1.4. Polyglutamine Deposits. Detection of polyglutamine deposits using polyQ-huntingtin provides interesting findings, which give a complete histopathological picture of HD progression. In wt rats, polyQ detects a normal polyglutamine domain huntingtin encoded by lower number (about 35 or less) of consecutive glutamine repeats; therefore, only fine polyQ deposits are spread in the nuclei of striatal neurons (Figure 8(a)). In contrast, the pathogenic alleles usually contain 39 or more glutamine repeats, which results in production of mhtt and increased density of intranuclear polyQ expression in relation to the progression of HD phenotype (Figures 8(b)–8(d)). It is necessary to emphasize that increased density/concentration of intranuclear polyQ deposits is also potentiatted by the shrinkage (decreased volume) of nuclei in degenerated neurons in course of the progression of NDP (compare Figures 8(a) and 8(b)–8(d)). Similarly, the number of affected polyQ+ glial cells significantly increases with advancing NDP (Figures 8(c) and 8(d)), most likely in relation to the development of reactive astrogliosis; that is, mhtt is probably preferentially
expressed by reactive astrocytes. Surprisingly, using polyQ-huntingtin antibody, neither typical large intranuclear nor neuropil aggregates were seen. Moreover, neurons in adjacent cortex also exhibit intranuclear but more cytoplasmic polyQ deposits; therefore, they are more densely stained in comparison with striatal neurons, particularly in tgHD rats (Figures 8(e)–8(g)). On the contrary, only few cortical glial cells express polyQ, which corresponds to the absence of typical reactive gliosis in this region. The presence of very densely labelled (hyperchromic) degenerated/shrunken cortical (primarily pyramidal) neurons—demonstrated also by other histological staining methods—unequivocally confirms that, in tgHDSI rats, NDP in the striatum is accompanied with the degeneration of cortical neurons (Figures 8(f) and 8(g)) alike in human HD brain.

Moreover, the highest density of deposits in shrunk/hyperchromic terminally degenerated neurons (less prominent in glial cells) corresponds to the hypothesis that accumulation of mhtt results in the cell death.

3.2. Glial Cells during Progression of HD. It is evident that the developments of changes in glial cell morphology, and certainly also in their function, are conditioned by the intensity and rate of neuronal degeneration in the context of the neuron-glia relationship.

3.2.1. Astrocytes. Protoplasmic astrocytes are the most numerous component of the striatal parenchyma. Despite their standard visualisation by detection of GFAP, most of them are GFAP-negative.

The shape of astrocytes changes during the progression of NDP; however specific prominent alterations occur only in human HD brains, where the astrogliosis gradually develops (Figures 10(b) and 10(c)). In tgHD rats, the main GFAP+ processes get coarser, albeit less branched. Indeed, the most distinct part of the processes (enlarged and densely GFAP+) becomes their vascular end-feet (Figures 9(b) and 9(c)). Hence, the main astrocytic processes and the perivascular
Figure 8: (a) Only fine polyQ deposits are spread in the nuclei of striatal neurons in control 6-month-old rats unlike (b) a higher density of polyQ deposits in age-matched tgHD rats; (c) significantly increased density of polyQ inclusions, in both neurons and some glial cells (yellow arrows), is already in 12-month-old tgHD rats and (d) particularly in aged (here 18-month-old) tgHD rats; increased density of polyQ expression is probably also influenced by the shrinkage of nuclei during the degeneration of neurons; the progression of rarefaction of the neuropil is also apparent. (e) In the cortex of 2-month-old wt rats, perinuclear polyQ positivity is only in some neurons, unlike increased concentration of polyQ (mhtt) deposits particularly within the cytoplasm, primarily of pyramidal neurons, in (f) 12-month- and (g) 18-month-old tgHD rats; in aged tgHD rats, the significant number of degenerated (hyperchromic) neurons is present (blue arrows); only few polyQ+ and subsequently degenerated glial cells (yellow arrows) and particularly loosening of the neuropil are also characteristic for the progression of NDP in the cortex of tgHD51 rats. Anti-polyQ counterstained with 0.1% methyl green. Bar 20 μm.

Figure 9: (a) In young (2-month-old) wt rats S100β+ astrocytes are predominantly GFAP-negative; with the progression of NDP in (b) 18-month-old tgHD rats and (c) 24-month-old tgHD rats the main GFAP+ processes become coarser, albeit less branched, and the most distinct are their vascular end-feet (thickening of the perivascular membrane in form of “rings”); the number of not only S100β+/GFAP− but also S100β+/GFAP+ astrocytes increases primarily around the vessels; the coexpression is seen mainly within the thick astrocytic processes terminating by the end-feet on the vessel wall. Anti-GFAP (red) + anti-S100β (green) + DAPI (blue). Bar 20 μm.
limiting membrane are the most prominent GFAP\textsuperscript{+} structures in striatal parenchyma, not only in brains of tgHD rats surviving for 12–24 months (Figures 9(b) and 9(c)), but also in old wt rats, as well as in postmortem specimens of HD patients (Figures 10(b) and 10(c)). Due to only slow development of neuronal degeneration in the striatum of tgHD rats, the subsequent astrogliosis progresses also slowly—with insignificant onset after 6 months of age of tgHD rats—and becomes more distinct just in 18–24-month-old animals (Figure 9(c)). Age-related changes not only are seen in old wt rats, but also participate in progression of reactive gliosis in tgHD rats. Less (in wt rats) or more (in tgHD rats) developed striatal atrophy is manifested in senescent rats by denser accumulation of (smaller) nuclei of neurons and glia (compare Figures 2(a)–2(c)).

In HD human brains, besides the gradually increased number of reactive astrocytes, their fine GFAP\textsuperscript{+} processes become numerous although shorter in comparison with control brains and of characteristic arborization, forming a fine loosely arranged network, whose density increases with the progression of the disease. Moreover, we identified the specific terminal swellings in most of densely GFAP\textsuperscript{+} processes, whose number and also size slowly but gradually increase with the progression of HD (Figures 10(b) and 10(c)).

Despite the fact that the astrocytes, engaged in NDP, are described as "reactive," it is necessary to point out that they are of quite different structure in comparison with typical reactive astrocytes appearing after the acute brain injury. First of all, in both HD patients and tgHD rats, generation of reactive astrocytes proceeds gradually and slowly, unlike the almost immediate appearance of reactive astrocytes after the acute brain damage. Indeed, their bodies are not significantly enlarged (hypertrophic); contrariwise, a part of them also undergoes the degeneration and they are scavenged by microglia (Figures 12(c), 13(c), and 13(d)). Additionally, enlarged GFAP\textsuperscript{+} vascular end-feet, which typically highlight the wall of vessels in developing NDP (Figures 9(b), 10(b), and 10(c)), and increased amount of GFAP\textsuperscript{+} gliofilaments forming thick bundles within the cytoplasm of reactive astrocytes belong to significant features of concomitant astrogliosis in brain of both tgHD rats and HD patients. On the contrary, we never found the reexpression of intermediate filaments nestin and vimentin, which is considerable feature of hypertrophic reactive astrocytes after the acute brain damage.

3.2.2. \textit{S100\textbeta} Protein-Positive Glia. \textit{S100\textbeta} protein is glial-specific and it is expressed primarily by astrocytes, although not by all of them. Since this protein participates in many processes related to glial-glial and neuronal-glial crosstalk, we were interested in relevance of \textit{S100\textbeta} expression by astrocytes in relation to developing NDP of HD phenotype. Surprisingly, the number of \textit{S100\textbeta}\textsuperscript{+} astrocytes is not markedly influenced by the progression of chronic NDP either in tgHD rats or in human HD brain. The majority of \textit{S100\textbeta}\textsuperscript{+}-positive astrocytes are GFAP-negative, primarily in healthy brain. Intensely \textit{S100\textbeta} labelled are cell bodies (incl. nuclei) and large processes terminated by end-feet. Although less prominent, expression is also in fine astrocytic processes. Since \textit{S100\textbeta}\textsuperscript{+} cells in the striatum are mainly the astrocytes, they may reflect the changes caused by the progression of NDP (Figures 9(b), 9(c), 10(b), and 10(c)), as well as by ageing process in controls. Such alterations in astrocyte immunoreactivity/morphology were primarily described on GFAP\textsuperscript{+} astrocytes but naturally affect all subtypes of astrocytes. In both NDP and ageing, bodies of numerous either \textit{S100\textbeta}\textsuperscript{+} or GFAP\textsuperscript{+} astrocytes slightly decrease in size and their processes become coarser (Figures 9 and 10). Moreover, the coexpression of \textit{S100\textbeta} and GFAP increases, although rather differently in tgHD rats and human HD brains. In tgHD rats, the coexpression is slightly enhanced in end-feet (Figures 10(b) and 10(c)), unlike significant coexpression in both the cytoplasm of cell bodies and end-feet in human HD brains (Figures 10(b) and 10(c)). It is likely that different intensity of \textit{S100\textbeta}/GFAP coexpression depends on a severity of the damage of striatal parenchyma which resulted, except others, in thickening of perivascular limiting membrane (i.e., vascular end-feet). Contrariwise, we could not confirm the expression of \textit{S100\textbeta} by NG2 glia either in controls or in relation to striatal NDP.
3.2.3. NG2 Glia (Polydendrocytes). They are closely related to the development of myelinating oligodendrocytes, whose precursors are considered. We were interested in their possible alterations related to the progression of NDP in tgHD rats and also in senescence. Due to technical reasons (particularly the length of formalin fixation and the use of paraffin sections only), we were not able to detect NG2 glia cells in postmortem samples of human brains. In the rat brain, we did not prove any significant changes either in their number or in morphology in a course of the development of NDP, even in ageing process. In all examined samples, they were numerous (e.g., they outnumbered the GFAP⁺ astrocytes) and large number of their fine branched processes forms a very dense three-dimensional network throughout the entire striatal parenchyma, particularly in the grey matter (Figures 11(a)–11(c)). We also did not prove colabelling of NG2 with astrocytic markers, such as GFAP or S100β, which might suggest that astrocytes in response to chronic slowly developing NDP are generated in prolonged time window.

3.2.4. Microglia. They represent a special type of professional phagocytes occurring only in CNS, which are spread out primarily within grey matter (Figures 12(a) and 13(a)), but in lower number they are present also in white matter. In agreement with previous studies we document their upregulation with the progression of NDP, particularly in advanced stages, in both tgHD51 rats and HD brains (Figures 12 and 13), unlike their only slowly growing number in ageing control animals. In the oldest (18–24-month-old) wt control rats, their number is evidently higher, which confirms physiological increase of neuronal degeneration in aged animals. Interesting morphological findings appeared in relation of microglia (Iba1⁺) to degenerated neurons (MAP2⁺). This double-staining enables...
to document the consequence of stages of neuronal degeneration and removal of neurons, including the accumulation of ingested debris inside the microglial cells (Figures 12(b) and 12(c)). Indeed, glial cells (mainly astrocytes) degenerate as well and are scavenged in both rat and human brain under the pathological (e.g., Figure 13(d)) as well as physiological conditions.

In human brain, in relation to advancing NDP, the growing number of microglia is also observed (Figure 13(b)), especially in comparison with normal control brains (Figure 13(a)). However, the large number of microglia is present only in relation to degenerated and scavenged neurons; when most of striatal neurons are destroyed (i.e., in seriously damaged CN - grade 4, 20-year ongoing clinical manifestation of HD), a subsequent decrease in number of microglia is detected (Figure 13(c)). Concurrently, the majority of remaining microglia (intensely Iba1+) are settled close to vessels (Figure 13(d)). By contrast, in the Pu of the same sample, degenerated scavenged neurons and therefore also the microglia were still present in a large amount.

In summary, the hallmark of NDP in tgHD51 rats is a slow degeneration of striatal neurons, manifested primarily by gradual decrease in size of neuronal bodies/nuclei (with maintenance of nucleo-cytoplasmic rate) accompanied with the rarefaction of neuropil. Using the quantitative analysis, we clearly demonstrated for the first time that the turn point in the progression of neurodegenerative process in tgHD51 rats is before the end of the first year of animal age. Then, between 12 and 24 months of age, the further progression is gradual but at a slower rate, resulting in death of many neurons. Moreover, we confirmed that the development of NDP within the striatum is accompanied with gradual degeneration of cortical, particularly pyramidal neurons. We also documented significant participation of the glia, of which function in the development of NDP is irreplaceable. Most prominent is the involvement of GFAP+ astrocytes, particularly their transformation into the specific type of reactive astrocytes. This transformation is responsible for alterations in a structure (and therefore also in a function) of the perivascular glial limiting membrane, loosening of neuropil, and other changes. Surprisingly, we cannot confirm noticeable changes in morphology or number of NG2 glia in tghD rats, unlike significant participation of microglia and, although less prominent, involvement of S100β+ cells in NDP.
in both tgHD and human HD brains. Certainly, the entire process is potentiated by ageing changes. Our results confirm the complexity of the entire process, in which the neuron-glial crosstalk is crucial.

4. Discussion

The aim of our study was primarily motivated by the absence of histopathological characteristics of chronic neurodegenerative process of HD phenotype in transgenic HD51 CAG rats, which, unlike the other transgenic animal models of HD, survive up to 2 years. Moreover, this transgenic model comprises relatively smaller number (51) of CAG repeats. Both mentioned hallmarks create conditions for similarity to the late-onset form of HD. For this reason, we tried to define to which extent is possible to make a parallel between rat tgHD model and real NDP in human HD brain from histopathological point of view. On the other hand, behavioural symptoms were already widely studied on these animals (see below).

Despite the fact that HD takes place exclusively within human brain and each type of existing animal models is not able to replicate completely mechanisms participating in NDP of the HD phenotype, transgenic models represent a crucial part in the field of the research on HD pathogenesis.

4.1. Mutant Huntingtin and Polyglutamine Deposits. It is generally known that HD is a neurodegenerative movement disorder caused by genetic mutation and morphologically characterized by progressive but selective loss of neurons, primarily within the striatum, followed by the development of reactive gliosis (e.g., [52]). Regardless of some in vitro studies which indicated formation of polyQ inclusions that reduce levels of mhtt and the risk of neuronal death [10, 11], it was suggested that the aberrant protein huntingtin (mhtt) with an expansion of N-terminal polyglutamine tract causes preferentially degeneration of striatal neurons in patients with HD (e.g., [6]). Moreover, a gain of a new toxic function of the mhtt results in the loss of former protective functions of wild-type htt, which ultimately leads to the death of neurons [8]. Accumulation of polyQ within the neurons and inside the neuropil is primarily described in a form of aggregates. Our findings showed fine polyQ-huntingtin-positive deposits within the nuclei of striatal neurons in control wt rats and their increase up to very dense accumulation in course of the progression of NDP in tgHD51 rats. On the other hand in cortical (particularly pyramidal) neurons, polyQ deposition were not only intranuclear but also particularly cytoplasmic. PolyQ-huntingtin antibody labels not only expanded polyglutamine (mhtt) but also wild-type (normal) huntingtin; therefore the deposits are also present in the brain of control rats. Hence, increased density of polyQ expression in tgHD51 rats is related to increased number of glutamine repeats, that is, to the accumulation of mhtt. Htt is particularly not only spread within the cytoplasm of neuronal bodies and dendrites [7] but also present in the nucleus [53]. Mhtt is present in both nuclear and cytoplasmic compartments, extended polyQ aggregated in the cytoplasm and then it is transported to the nucleus [54]. Increasing concentration of the mhtt in the nucleus accelerates the onset and progression of NDP; however, also extranuclear polyQ might contribute to the initiation of NDP [55]. The same but almost exclusively intranuclear polyQ deposits were also found in glial cells in both brain regions. Accumulated mhtt causes the dysfunction of astrocytes, particularly in relation to glutamate uptake, since it decreases the expression of glutamate transporters. This impairment may promote vulnerability, especially of striatal medium-sized spiny neurons, to the excitotoxic damage and their degeneration (e.g., [12, 13]). Astrocytes expressing mhtt transform into reactive phenotype, which is characterized by markedly decreased expression of glutamate transporters (GLAST and GLT-1) and glutamate uptake. These alterations appear already in early stages of HD (grade 0) and progress in a course of the disease. Therefore, it was suggested that the presence of mhtt in astrocytes and their conversion into reactive glia may contribute to HD pathogenesis [13].

4.2. Reactive Astrogliosis. Reactive astrogliosis is a gradual continuous process of progressive alterations in gene expression and cellular changes. The intensity and extent of the reactive gliosis are determined primarily by signals from damaged cells (e.g., [56, 57]). Up to now, the origin and the way by which the increased number of astrocytes appears in damaged CNS are not fully elucidated and still remain a matter of intensive debate. Considering various types of CNS disorders, marked differences in development of astrogliosis should be taken into the account. During acute CNS injury, reactive gliosis develops within two days and reaches its maximum 1-2 weeks following the insult, while chronic injuries, such as neurodegenerative diseases, are characterised by slow development of astrogliosis, which may last even several years in humans [58].

Owing to the fact that only very low (if any) response of neural progenitors to the CNS damage is found in all nonneurogenic regions, the source for generation of GFAP+ reactive astrocytes remains under discussion—two plausible possibilities are proposed: (1) transformation or dedifferentiation from resident astrocytes which has been confirmed after different neurotoxic lesions in rodent brain (e.g., [59, 60]) or the activation of "quiescent" protoplasmic astrocytes (a subset of GFAP+ astrocytes) acquiring stem cell properties in adult mouse cerebral cortex after acute injury [61]; (2) differentiation of glial progenitors expressing Olig2 and NG2 [62, 63]. For that reason we were surprised with the absence of any obvious involvement of NG2 glia and principally also S100β-positive astrocytes in reactive gliosis. On the contrary, both mentioned possibilities were described in relation to the acute lesion of rodent brain. How the generation of reactive astrocytes occurs in human brain suffering from chronic neurodegenerative process or in brain of transgenic animals modelling neurodegenerative diseases, as well as the participation of NG2 in the progression of NDP, particularly in HD patients, remains unclear.

It is evident that the development of reactive gliosis and the alterations in astrocyte morphology are conditioned by the intensity and rate of neuronal degeneration in
the context of the neuron-glia relationship [64]. Our findings also document significant difference between typical reactive astrocytes, which change their phenotype in reaction to the acute brain injury or excitotoxic lesion, used formerly as an animal model of HD (e.g., [58, 65]) and "reactive" astrocytes developing during slow progression of chronic neurodegenerative process of HD phenotype. The most conspicuous are changes in expression of GFAP, that is, in the number and arrangement of gliofilaments (the principal astrocytic intermediate filaments) within the cytoplasm. Reactive astrocytes become more stellate with only few but coarse main processes, especially those terminating as the end-feet on the vessel wall. They are intensely labelled for GFAP, due to not only increased amount of GFAP\(^+\) gliofilaments but particularly their accumulation to thick bundles (e.g., [34, 64]). This alteration is evident in both tgHD and human HD brains and progresses with the development of NDP. Furthermore, this process occurs not only in HD, but also in other neurodegenerative diseases, such as Parkinson's (e.g., [48, 56]) and Alzheimer's disease (e.g., [66]). Indeed, similar changes, although to a lesser extent, are typical for astrocytes in a course of ageing in both human and rodents (e.g., [66]). Significant for those “reactive” astrocytes involved in NDP is also the absence of reexpression of other intermediate filaments, nestin and vimentin (abundantly expressed in immature astrocytes), whose adaptation is characteristic for immediate activation of astrocytes not only in case of the acute brain injury (e.g., the formation of the glial scar) but also in neurotoxic models of HD [64]. Moreover, these astrocytes do not become markedly hypertrophic (e.g., [34]).

4.3. Neuronal-Glial-Vascular Unit. Except for others, very important is also the relationship of astrocytes to the vessels. Our previous findings documented the thickening of end-feet (and this way of the perivascular limiting membrane), which markedly outlines vessel walls forming typical “rings” with the progression of NDP in excitotoxic rat model of HD [64]. Our findings also demonstrate that those coarser end-feet not only are intensely GFAP-positive but also frequently coexpress \(\alpha\)-S100\(\beta\) protein in both tgHD rat and HD human brains. These gradual alterations in the architecture of the vascular end-feet might contribute to the restriction of transport or diffusion across the blood-brain interface (e.g., [31, 56]). Additionally, the specific enlargement at the tips of astrocytic processes in a form of intensely GFAP-positive “terminal swellings” was found in advancing NDP in human HD brains (grades 3 and 4). However, there is no evidence, which structure in neuropil is in contact with these modified endings. Hypothetically, they might belong to those extensions that lost contact with any opposite structure. In agreement with the other authors, we have indicated participation of ageing changes [67] in the above-mentioned alterations of astrocytic morphology in the oldest groups of control animals.

4.4. CNS Phagocytes: Microglia and Astrocytes. It is also well known that astrocytes are involved in degradation of different metabolites and toxic products under the normal conditions. Their ability to function as phagocytes is then enhanced under the pathological conditions (e.g., [68]). It was proposed that chronically activated astrocytes and microglia can damage neurons via release of highly toxic products (e.g., [66]) and also that microglia play an important role in pathogenesis of Parkinson's disease. This latter suggestion is based on the fact that, with progressive neuronal loss, increasing amounts of \(\alpha\)-synuclein and neuromelanin accumulate in the extracellular space due to dysfunction in microglia phagocytic ability [49]. In general, debris accumulation is supposed to be one of key features of the progression (if not direct initiation) of neurodegenerative diseases.

4.5. NG2 Glia. To our surprise, we did not find any significant alterations in number and morphology of NG2 polydendrocytes in the presence of pathology. They formed a typical dense network in all tested groups of tgHD and wt rats. Due to technical reasons, we were unfortunately not able to follow them in postmortem specimens of human brains, either with HD or intact. It is probably the main reason why the involvement of NG2 glia in NDP has not been reported yet in brains of HD patients. The elegant study employing postmortem specimens of human brain tissue with multiple sclerosis (MS) lesions or glioma (using both frozen and paraffin sections) was published by Staugaitis and Trapp [44]. They also discussed difficulties with detection of NG2 glia in routinely processed surgical and autopsy tissue. However, no obvious decrease in density of NG2 glia was found in the grey matter of cerebral cortex with MS lesions [44, 69]. Indeed, most of other studies which reported the relationship of NG2 glia to human CNS pathology are based only on \textit{in vitro} experiments (e.g., [70]).

4.6. Participation of Neurons and Glial Cells in Neurodegenerative Process. It is obvious that glia, particularly GFAP-positive astrocytes, play a critical role in the progression of NDP. Nevertheless, their involvement is always in a context of changes affecting simultaneously all components—cellular and noncellular—of the nervous tissue microenvironment. Also microglia is suggested to be an important player in complex response of nervous tissue to the chronic damage, principally by the activation of cascade of the immune response.

The evaluation of the contribution of GFAP\(^+\) astrocytes to neurodegenerative process remains still unclear, albeit their dual role—neuroprotective and neurodegenerative—was already mentioned by some authors (e.g., [27, 56, 71]). On the one hand, astrocytic degeneration accompanying degeneration of the neurons obviously participates in the processes resulting in disintegration of the nervous tissue (loosening of the neuropil, thickening of perivascular glial limiting membrane, and others). On the other hand, there are some indications that changes in astrocyte character and function belong to neuroprotective mechanisms in damaged nervous tissue.

Regardless of the interesting and challenging findings related to the different types of glial cells, the degeneration and loss of neurons, primarily within the striatum,
accompanied with loosening of the neuropil still remain the hallmark of HD. However, the disintegration of the neuropil not only results from gradual reduction of neuronal processes, but also includes the alterations of the glial cells. Indeed, regression of the neuropil represents the progressive disruption of the striatal microenvironment, including the vascular niche, essential for the viability and functioning of all the components of striatal tissue, which even more contributes to worsening of the entire process. The reduction of the grey matter results in a severe brain (primarily striatal) atrophy in advanced NDP.

4.7. Rats Transgenic for HD. Transgenic HD51 CAG rats were used also by other research groups, mainly to validate changes in their behaviour, which indicates impaired striatal function (e.g., [9, 21–24]). The tests proved an early learning and memory impairment (starting between 9 and 12 months) and delayed motor deficits (with the onset around 12 months); moreover, these deficits develop prior to any diagnosed striatal dysfunction. Additionally, age- and genotype-dependent changes in psychomotor performance and in the frequency of choreiform movements were proved in homozygous, less heterozygous tgHD rats in comparison with controls at the age of 15 months and particularly at 20 months [22]. Concerning morphological evaluation, it was shown that polyQ aggregates appear within the striatum of tgHD rats at 12 months of age [9, 23] and the density of their accumulation increases with age, which is consistent with our observations. Furthermore, the quantitative analysis of total striatal volume was carried out in animals from 3 to 15 months of age (using stereological method), which confirmed significant gradual decrease in striatal volume from 12 to 15 months in tgHD rats compared with wt littermates [9] or in 12-month-old rats (compared with 6-month-old and wt rats), respectively [24]. The only reference of Kántor and coauthors [24] provides quantitative analysis of total numbers of neurons and neuronal density in the striatum and a part of frontal cortical layer V in groups of 6- and 12-month-old tgHD51 and wt rats. The results related to the striatum are comparable with our observations. However, the hallmark of neurodegenerative process in the brain of tgHD rats is gradual decrease in size of striatal neurons, unlike the significant decrease in their number in postmortem samples of HD brains. Therefore, we used median diameter of neuronal nuclei to document the onset and progression of NDP in 5 groups of tgHD rats and age-matched wt rats. Nevertheless, to analyse the density of striatal neurons (i.e., their number per defined square unit) becomes rather problematic in the oldest rats (1.5–2 years old) due to significant shrinkage of the striatum. Kántor and coauthors also concluded that, unlike striatal neurons, the cortical neurons (in layer V) did not reveal significant degeneration in 12-month-old tgHD rats. We documented the presence of significant number of hyperchromic degenerated neurons in this age in comparison with age-matched control rats, which is consistent with changes within the cortex of human HD brain [2]. Moreover, already in 6 months old tgHD rats, degenerated cortical neurons appeared. On the other hand, in both tgHD51 rats and HD patients, the extent of neuronal degeneration in the cortex never reaches extensive degeneration within the striatum; therefore, it cannot be accompanied with reactive gliosis.

5. Conclusions

In this study, histopathological features, significant for alterations in human brains suffered from HD and brains of tgHD51 CAG rats, were compared. The significant difference is primarily in the intensity of neuronal degeneration which, even in the oldest rats, does not reach the severity of the damage characteristic for advanced stages of HD in humans. In tgHD51 rats, quite large amounts of striatal neurons display only gradual decrease in their size and do not fully degenerate and disappear until the death of animal (at about 2 years of age). Therefore, also concomitant reactive astrogliosis is not extensive in old tgHD rats, unlike the advanced stages of HD in humans. On the other hand, striatal atrophy (the reduction of grey matter) develops gradually, and it is distinguishable from 12 months of age in tgHD rats, manifested primarily by compensatory enlargement of lateral brain ventricles. The reason for striatal shrinkage is the same in rats and humans; it originates from the gradual degeneration of neurons resulting in rarefaction of the neuropil including the alterations in the density and character of synapses. Our data also support the view that all types of CNS glial cells play an important, irreplaceable role in neurodegenerative process. There are different indications that changes in their character and function try to balance the development of serious irreversible damage of the striatum as long as possible. However, when this battle exceeds all their capacities, the system collapses and their involvement becomes detrimental, finally resulting in death of an individual. All the available results in this field directly or indirectly confirm that the response of nervous tissue to any damage is always complex (moreover in relation to the entire organism) and therefore has to be considered in this context.

To the best of our knowledge, our findings are the first to document that tgHD51 CAG rats can be used as a valid animal model for detailed histopathological studies related to HD in human. On the other hand, since HD occurs only in humans and we are not able to reproduce fully this process in animals till now, the interpretation of all findings has to be always carefully weighted and sufficiently critical.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

All authors have read and approved the final paper.

Acknowledgments

The authors would like to thank M. Hetešová, S. Vrchotová, Z. Komárková, J. Hošková, laboratory technicians at the
Department of Histology and Embryology, and H. Pavlíková at the Department of Cellular Neurophysiology, for excellent technical assistance, and also D. Ježková from Radioisotope Laboratories and Vivarium for perfect care of rats. This study was supported by the Charles University Research Program PRVOUK P3706140/06 and PRVOUK P3706140/09 and by the Grant Agency of the Czech Republic (GAČR) P304/12/G069.

References

[1] T. Foroud, J. Gray, J. Ivashina, and P. M. Conneally, “Differences in duration of Huntington’s disease based on age at onset,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 1, pp. 52–56, 1999.

[2] J. P. Vonsattel, R. H. Myers, T. J. Stevens, R. J. Ferrante, E. D. Bird, and E. P. Richardson Jr., “Neuropathological classification of Huntington’s disease,” Journal of Neuropathology and Experimental Neurology, vol. 44, no. 6, pp. 559–577, 1985.

[3] J. F. Gusella, “Huntington disease,” in Encyclopedia of Life Sciences, Nature Publishing Group, 2001, http://www.els.net.

[4] J. F. Gusella, N. S. Wexler, P. M. Conneally et al., “A polymorphic DNA marker genetically linked to Huntington’s disease,” Nature, vol. 306, no. 5940, pp. 234–238, 1983.

[5] M. E. MacDonald, C. M. Ambrose, M. P. Duyao et al., “A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes,” Cell, vol. 72, no. 6, pp. 971–983, 1993.

[6] N. Aronin, K. Chase, C. Young et al., “CAG expansion affects the expression of mutant huntingtin in the Huntington’s disease brain,” Neuron, vol. 15, no. 5, pp. 1193–1201, 1995.

[7] M. DiFiglia, E. Sapp, K. Chase et al., “Huntington is a cytoplasmic protein associated with vesicles in human and rat brain neurons,” Neuron, vol. 14, no. 5, pp. 1075–1081, 1995.

[8] M. Borrell-Pagès, D. Zala, S. Humbert, and F. Saudou, “Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies,” Cellular and Molecular Life Sciences, vol. 63, no. 22, pp. 2642–2660, 2006.

[9] H. P. Nguyen, P. Kobbe, H. Rahne et al., “Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington’s disease,” Human Molecular Genetics, vol. 15, no. 21, pp. 3717–3719, 2006.

[10] M. Arrasate, S. Mitra, E. S. Schweitzer, M. R. Segal, and S. Finkbeiner, “Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death,” Nature, vol. 431, no. 7010, pp. 805–810, 2004.

[11] J. Miller, M. Arrasate, B. A. Shaby, S. Mitra, E. Masliah, and S. Finkbeiner, “Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into Huntington’s disease molecular pathogenesis,” Journal of Neuroscience, vol. 30, no. 31, pp. 10541–10550, 2010.

[12] J. Y. Shin, Z. H. Fang, Z. X. Yu, C. E. Wang, S. Li, and X. Li, “Expression of mutant huntingtin in gli cells contributes to neuronal excitotoxicity,” Journal of Cell Biology, vol. 171, no. 6, pp. 1001–1012, 2005.

[13] M. Faideau, J. Kim, K. Cormier et al., “In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington’s disease subjects,” Human Molecular Genetics, vol. 19, no. 15, pp. 3053–3067, 2010.

[14] S. E. Browne and M. F. Beal, “Oxidative damage in Huntington’s disease pathogenesis,” Antioxidants and Redox Signaling, vol. 8, no. 11-12, pp. 2061–2073, 2006.

[15] M. A. Pouladi, A. J. Morton, and M. R. Hayden, “Choosing an animal model for the study of Huntington’s disease,” Nature Reviews Neuroscience, vol. 14, no. 10, pp. 708–721, 2013.

[16] L. Mangiarini, K. Sathasivam, M. Seller et al., “Exon I of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice,” Cell, vol. 87, no. 3, pp. 493–506, 1996.

[17] R. J. Ferrante, “Mouse models of Huntington’s disease and methodological considerations for therapeutic trials,” Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1792, no. 6, pp. 506–520, 2009.

[18] J. M. Gil and A. C. Rego, “The R6 lines of transgenic mice: a model for screening new therapies for Huntington’s disease,” Brain Research Reviews, vol. 59, no. 2, pp. 410–431, 2009.

[19] S. W. Davies, M. Turmaine, B. A. Cozens et al., “Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation,” Cell, vol. 90, no. 3, pp. 537–548, 1997.

[20] H. S. von Hörsten, I. Schmitt, H. P. Nguyen et al., “Transgenic rat model of Huntington’s disease,” Human Molecular Genetics, vol. 12, no. 6, pp. 617–624, 2003.

[21] K. D. Fink, J. Rossignol, A. T. Crane et al., “Early cognitive dysfunction in the HD S1 CAG transgenic rat model of Huntington’s disease,” Behavioral Neuroscience, vol. 126, no. 3, pp. 479–487, 2012.

[22] C. Cao, Y. Temel, A. Blokland et al., “Progressive deterioration of reaction time performance and choreiform symptoms in a new Huntington’s disease transgenic rat model,” Behavioral Brain Research, vol. 170, no. 2, pp. 257–261, 2006.

[23] R. D. Kirch, P. T. Meyer, S. Geisler et al., “Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington’s disease,” Behavioural Brain Research, vol. 239, no. 1, pp. 25–26, 2013.

[24] O. Kántor, Y. Temel, C. Holzmann et al., “Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington’s disease transgenic rats,” Neurobiology of Disease, vol. 22, no. 3, pp. 538–547, 2006.

[25] A. Verkhratsky and A. Butt, Glial Neurobiology, John Wiley & Sons, Chichester, UK, 2007.

[26] H. K. Kimelberg, “Functions of mature mammalian astrocytes: a current view,” Neuroscientist, vol. 16, no. 1, pp. 79–106, 2010.

[27] D. D. Wang and A. Bordey, “The astrocyte odyssey,” Progress in Neurobiology, vol. 86, no. 4, pp. 342–367, 2008.

[28] A. Araque, V. Pardina, R. P. Sanzgiri, and P. G. Haydon, “Tripartite synapses: glia, the unacknowledged partner,” Trends in Neurosciences, vol. 22, no. 5, pp. 208–215, 1999.

[29] M. Nederpeld, J. J. Rodríguez, and A. Verkhratsky, “Glial calcium and diseases of the nervous system,” Cell Calcium, vol. 47, no. 2, pp. 140–149, 2010.

[30] M. Nederpeld, B. Ransom, and S. A. Goldman, “New roles for astrocytes: redefining the functional architecture of the brain,” Trends in Neurosciences, vol. 26, no. 10, pp. 523–530, 2003.

[31] T. M. Mathiisen, K. P. Lehre, N. C. Danbolt, and O. P. Ottersen, “The perivascular astroglial sheath provides a complete covering of the brain microvessels: An electron microscopic 3D reconstruction,” GLIA, vol. 58, no. 9, pp. 1094–1103, 2010.

[32] L. F. Eng, B. Gerstl, and J. J. Vanderhaeghen, “A study of proteins in old multiple sclerosis plaques,” Transactions of the American Society for Neurochemistry, vol. 1, p. 42, 1970.
[33] M. V. Sofroniew, "Reactive astrocytes in neural repair and protection," Neuroscientist, vol. 11, no. 5, pp. 400–407, 2005.

[34] M. Pekny and M. Pekna, "Astrocyte intermediate filaments in CNS pathologies and regeneration," Journal of Pathology, vol. 204, no. 4, pp. 428–437, 2004.

[35] S. R. Clarke, A. K. Shetty, J. L. Bradley, and D. A. Turner, "Reactive astrocytes express the embryonic intermediate neurofilament nestin," NeuroReport, vol. 5, no. 15, pp. 1885–1888, 1994.

[36] C. Elasson, C. Sahlgren, C.-H. Berthold et al., "Intermediate filament protein partnership in astrocytes," The Journal of Biological Chemistry, vol. 274, no. 34, pp. 23996–24006, 1999.

[37] D. B. Zimmer, E. H. Cornwall, A. Landar, and W. Song, "The S100 protein family: history, function, and expression," The Brain Research Bulletin, vol. 37, no. 4, pp. 417–429, 1995.

[38] M. Rothermundt, M. Peters, J. H. M. Prehn, and V. Arolt, "S100 protein in brain damage and neurodegeneration," Microscopy Research and Technique, vol. 60, no. 6, pp. 614–632, 2003.

[39] B. E. Boyes, S. U. Kim, V. Lee, and S. C. Sung, "Immunohistochemical co-localization of S-100b and the glial fibrillary acidic protein in rat brain," Neuroscience, vol. 17, no. 3, pp. 857–865, 1986.

[40] J. Steiner, H. Bernstein, H. Bielau et al., "Evidence for a wide extra-astrocytic distribution of S100B in human brain," BMC Neuroscience, vol. 8, article 2, pp. 1–10, 2007.

[41] A. Nishiyama, K. J. Dahlin, J. T. Prince, S. R. Johnstone, and W. B. Stallcup, "The primary structure of NG2, a novel membrane-spanning proteoglycan," Journal of Cell Biology, vol. 114, no. 2, pp. 359–371, 1991.

[42] A. Nishiyama, "Polydendrocytes: NG2 cells with many roles in development and repair of the CNS," Neuroscientist, vol. 13, no. 1, pp. 62–76, 2007.

[43] R. Wigley, N. Hamilton, A. Nishiyama, F. Kirchhoff, and A. M. Butt, "Morphological and physiological interactions of NG2-glia with astrocytes and neurons," Journal of Anatomy, vol. 210, no. 6, pp. 661–670, 2007.

[44] S. M. Staugaitis and B. D. Trapp, "NG2-positive glia in the human central nervous system," Neuron Glia Biology, vol. 5, no. 3–4, pp. 35–44, 2009.

[45] G. W. Kreutzberg, "Microglia: a sensor for pathological events in the CNS," Trends in Neurosciences, vol. 19, no. 8, pp. 312–318, 1996.

[46] G. Ellrichmann, C. Reick, C. Saft, and R. A. Linker, "The role of the immune system in Huntington's disease," Clinical and Developmental Immunology, vol. 2013, Article ID 541259, 11 pages, 2013.

[47] E. Sapp, K. B. Kegel, N. Aronin et al., "Early and progressive accumulation of reactive microglia in the Huntington disease brain," Journal of Neuropathology and Experimental Neurology, vol. 60, no. 2, pp. 161–172, 2001.

[48] G. M. Halliday and C. H. Stevens, "Glia: initiators and progressors of pathology in Parkinson's disease," Movement Disorders, vol. 26, no. 1, pp. 6–17, 2011.

[49] A. Aguzzi, B. A. Barres, and M. L. Bennett, "Microglia: scapegoat, saboteur, or something else?" Science, vol. 339, no. 6116, pp. 156–161, 2013.

[50] K. Biber, T. Owens, and E. Boddeke, "What is microglia neurotoxicity (Not)?" Glia, vol. 62, no. 6, pp. 841–854, 2014.

[51] L. W. Swanson, Brain Maps: Structure of the Rat Brain, Elsevier, 2nd edition, 1998.

[52] J. M. Gil and A. C. Rego, "Mechanisms of neurodegeneration in Huntington's disease," European Journal of Neuroscience, vol. 27, no. 11, pp. 2803–2820, 2008.

[53] K. B. Kegel, A. R. Meloni, Y. Yi et al., "Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription," The Journal of Biological Chemistry, vol. 277, no. 9, pp. 7466–7476, 2002.

[54] A. Kazantsev, E. Preisinger, A. Dranovsky, D. Goldgaber, and D. Housman, "Insoluble detergent-resistant aggregates form between pathological and non-pathological lengths of polyglutamine in mammalian cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11404–11409, 1999.

[55] C. L. Benn, C. Landles, H. Li et al., "Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease," Human Molecular Genetics, vol. 14, no. 20, pp. 3065–3078, 2005.

[56] M. V. Sofroniew and H. V. Vinters, "Astrocytes: biology and pathology," Acta Neuropathologica, vol. 119, no. 1, pp. 7–35, 2010.

[57] Y. Mazurová, I. Látr, J. Osterreicher, and I. Gunčová, "Progressive reparative gliosis in aged hosts and interferences with neural grafts in an animal model of Huntington's disease," Cellular and Molecular Neurobiology, vol. 26, no. 7–8, pp. 1423–1441, 2006.

[58] Y. Mazurová, I. Gunčová, I. Látr, and E. Rudolf, "Intervention of proliferation and differentiation of endogenous neural stem cells in the neurodegenerative process of Huntington's disease phenotype," CNS & Neurological Disorders: Drug Targets, vol. 10, no. 4, pp. 486–499, 2011.

[59] D. Schiffer, M. T. Giordana, P. Cavalla, M. C. Vigliani, and A. Attanasio, "Immunohistochemistry of glial reaction after injury in the rat: Double stainings and markers of cell proliferation," International Journal of Developmental Neuroscience, vol. 11, no. 2, pp. 269–280, 1993.

[60] B. Wachter, S. Schürger, J. Rolinger et al., "Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes," Cell and Tissue Research, vol. 342, no. 2, pp. 147–160, 2010.

[61] A. Buffo, I. Rite, P. Tripathi et al., "Origin and progeny of reactive gliosis: a source of multipotent cells in the injured brain," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 9, pp. 3581–3586, 2008.

[62] T. Magnus, T. Coksaygan, T. Korn et al., "Evidence that nucleocytoplasmic Olig2 translocation mediates brain-injury-induced differentiation of glial precursors to astrocytes," Journal of Neuroscience Research, vol. 85, no. 10, pp. 2126–2137, 2007.

[63] P. Honsa, H. Pivonkova, D. Dzamba, M. Filipova, and M. Anderova, "Polydendrocytes display large lineage plasticity following focal cerebral ischemia," PLoS ONE, vol. 7, no. 5, Article ID e36816, 2012.

[64] I. Gunčová, I. Látr, and Y. Mazurová, "The neurodegenerative process in an neurotoxic rat model and in patients with Huntington's disease: histopathological parallels and differences," Acta Histochemica, vol. 113, no. 8, pp. 783–792, 2011.

[65] Y. Mazurová, E. Rudolf, I. Gunčová, and I. Látr, "The activation of adult endogenous neural stem cells by neurodegenerative process within the striatum in an animal model of Huntington's disease," in Progress in Stem Cell Applications, A. V. Faraday and J. T. Dyer, Eds., pp. 309–337, Nova Science Publishers, New York, NY, USA, 2008.

[66] I. Blasko, C. Hummel, and B. Grubeck-Loebenstein, "Glial cells: astrocytes and oligodendrocytes during normal brain aging," Encyclopedia of Neuroscience, pp. 743–747, 2009.
[67] M. L. Cotrina and M. Nedergaard, “Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis,” *Journal of Neuroscience Research*, vol. 67, no. 1, pp. 21–29, 2002.

[68] J. D. Sokolowski and J. W. Mandell, “Phagocytic clearance in neurodegeneration,” *The American Journal of Pathology*, vol. 178, no. 4, pp. 1416–1428, 2011.

[69] A. Chang, A. Nishiyama, J. Peterson, J. Prineas, and B. D. Trapp, “NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions,” *Journal of Neuroscience*, vol. 20, no. 17, pp. 6404–6412, 2000.

[70] H. M. Nielsen, D. Ek, and U. Avdic, “NG2 cells, a new trail for Alzheimer’s disease mechanisms?” *Acta Neuropathologica Communications*, vol. 1, no. 1, p. 7, 2013.

[71] N. J. Maragakis and J. D. Rothstein, “Mechanisms of disease: astrocytes in neurodegenerative disease,” *Nature Clinical Practice Neurology*, vol. 2, no. 12, pp. 679–689, 2006.